Skip to content

MiniMed Group MMED Italy — Accrued rebates, noncurrent

Similar metrics at other companies

Indivior Pharmaceuticals, Inc.
 logo
INDVAccrued Rebates, Returns, and Promotions
$551M-18.4%
WD-40 Company logo
WDFCRebate/Other Discounts — Accrued liabilities
$11.8M-20.3%
Supernus Pharmaceuticals logo
SUPNAccrued product returns and rebates
$189.72M+11.5%
Lantheus Holdings logo
LNTHAccrued Rebates And Discounts Current
$69.88M
Organon logo
OGNInt’l — Accrual for rebates
$180M+16.1%
Krystal Biotech, Inc. logo
KRYSAccrued rebates
$70.72M+49.2%

Other financials

Income statement

See full
Revenue$790.0M+15.0%
Gross profit$362.0M-8.4%
Operating income-$100.0M-576%
Net income-$119.0M-1,090%
EPS (diluted)-$0.47-1,075%

Balance sheet

See full
Cash & equivalents$10.0M0.0%
Total debt$61.0M
Total equity$3.5B-0.7%
Total assets$4.3B

Cash flow

See full
Operating cash flow-$27.0M-147%
CapEx$167.0M+22.8%
Free cash flow-$194.0M-146%

Valuation

See full
Market cap$3.86B

Returns & leverage

See full
Debt / equity
Current ratio1.6×

Where this comes from

Reported directly by MiniMed Group in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerRefundLiabilityNoncurrent.

The official record: MiniMed Group ’s 10-Q, filed April 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiniMed Group 's italy — accrued rebates, noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiniMed Group 's italy — accrued rebates, noncurrent?
MiniMed Group (MMED) reported italy — accrued rebates, noncurrent of $48M in Q1 2026.
What does italy — accrued rebates, noncurrent mean?
This represents the long-term portion of estimated rebates owed to healthcare providers, distributors, or government entities in Italy for medical device sales. It captures future financial obligations that extend beyond the next fiscal year, often related to volume-based incentives or long-term pricing agreements. Tracking this provides insight into the company's long-term pricing strategy and potential future cash outflows.